Want to see IN:ROSSARI full AI Analyst Report?

Rossari Biotech Ltd (ROSSARI) Price & Analysis

2 Followers

ROSSARI Stock Chart & Stats

₹583.95

₹39.25(5.10%)

At close: Jan 08 4:00 PM EST

₹583.95

₹39.25(5.10%)

Day’s Range― - ―

52-Week Range₹372.90 - ₹670.10

Previous CloseN/A

Volume112.05K

Average Volume (3M)3.58K

Market Cap

₹24.28B

Enterprise Value₹25.58B

Total Cash (Recent Filing)₹1.15B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)16.5

Beta1.20

Next Earnings

Jan 18, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.11%

Share Statistics

EPS (TTM)27.22

Shares Outstanding55,394,115

10 Day Avg. Volume4,202

30 Day Avg. Volume3,576

Financial Highlights & Ratios

PEG Ratio1.51

Price to Book (P/B)1.57

Price to Sales (P/S)0.87

P/FCF Ratio-9.55

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)28.2

Revenue Forecast (FY)₹26.52B

Bulls Say, Bears Say

Bulls Say

Broad-based Revenue GrowthGrowth across all three divisions, supported by value-added products and higher customer wallet share, indicates broad demand rather than reliance on one narrow market. This diversification can support more resilient revenue expansion and improve operating leverage as volumes scale over the next several quarters.

Export And International ExpansionRising exports and the Thailand blending facility extend Rossari’s customer reach while enabling customized formulations and faster regional delivery. A larger international revenue base can diversify end-market demand, support higher-value products, and strengthen the company’s position in overseas specialty-chemical markets.

Improving Debt And Working CapitalRecent debt reduction and better working-capital discipline improve financial flexibility and reduce funding pressure on the operating business. If sustained, lower debtor and inventory intensity can strengthen cash conversion, support continued investment, and make the balance sheet more resilient as capacity expands.

Bears Say

Weak Cash ConversionPersistently weak free cash flow limits the company’s ability to fund expansion internally and increases reliance on borrowing or working-capital financing. The gap between reported earnings and cash generation could constrain investment flexibility and make execution more sensitive to changes in customer collections or inventory needs.

Rising Historical LeverageAlthough recent borrowings declined, the longer-term increase in debt has raised leverage relative to earlier periods and adds financial obligations to a business with volatile cash generation. Higher borrowing can restrict capital allocation choices and reduce the buffer available if growth investments take longer to mature.

Core B2B Margin PressureMargin compression in the core B2B business shows that strong volume growth is not fully translating into operating profit. Freight inflation and raw-material costs that cannot be completely passed through may keep profitability below potential, limiting earnings scalability until mix, pricing, or cost conditions improve.

Rossari Biotech Ltd News

Rossari Biotech Posts Record Quarter Amid Cost Headwinds

Rossari Biotech Ltd (($IN:ROSSARI)) has held its Q2 earnings call. Read on for the main highlights of the...

17h ago

Rossari Biotech Releases Q2 and H1 FY27 Earnings Presentation

The latest update is out from Rossari Biotech Ltd ( ($IN:ROSSARI) ). Rossari Biotech Limited operates in the...

2d ago

Rossari Biotech Delivers Record Q2 Results and Plans Saudi Expansion

Rossari Biotech Ltd ( ($IN:ROSSARI) ) has shared an announcement. Rossari Biotech reported its highest-ever quarterly revenue of...

2d ago

Rossari Biotech Publishes Unaudited September 2026 Consolidated Results in Newspapers

Rossari Biotech Ltd ( ($IN:ROSSARI) ) just unveiled an announcement. Rossari Biotech Ltd has published in Financial Express...

2d ago

Rossari Biotech Sets July 20 Investor Call on Q1 FY27 Results

Rossari Biotech Ltd ( ($IN:ROSSARI) ) has issued an update. Rossari Biotech Ltd has scheduled an earnings conference...

3M ago

Rossari Biotech Publishes AGM Notice and Details of E-Voting Facility

Rossari Biotech Ltd ( ($IN:ROSSARI) ) has shared an update. Rossari Biotech has notified exchanges that it has...

4M ago

Rossari Biotech sets July 20 virtual AGM, proposes dividend and related-party approvals

An announcement from Rossari Biotech Ltd ( ($IN:ROSSARI) ) is now available. Rossari Biotech Ltd has scheduled its...

4M ago

Rossari Biotech Releases Integrated Sustainability Report for FY 2025-26

Rossari Biotech Ltd ( ($IN:ROSSARI) ) has issued an announcement. Rossari Biotech Limited has released its Business Responsibility...

4M ago

Rossari Biotech dispatches AGM, annual report access details to non-email shareholders

Rossari Biotech Ltd ( ($IN:ROSSARI) ) has shared an update. Rossari Biotech has informed stock exchanges that it...

4M ago

Rossari Biotech Faces Court Challenge to Arbitration Award in Unitop Acquisition Dispute

Rossari Biotech Ltd ( ($IN:ROSSARI) ) has shared an announcement. Rossari Biotech has disclosed that the sellers of...

5M ago

ROSSARI FAQ

What was Rossari Biotech Ltd’s price range in the past 12 months?

Rossari Biotech Ltd lowest stock price was ₹372.90 and its highest was ₹670.10 in the past 12 months.

What is Rossari Biotech Ltd’s market cap?

Rossari Biotech Ltd’s market cap is ₹24.28B.

When is Rossari Biotech Ltd’s upcoming earnings report date?

Rossari Biotech Ltd’s upcoming earnings report date is Jan 18, 2027 which is in 90 days.

How were Rossari Biotech Ltd’s earnings last quarter?

Rossari Biotech Ltd released its earnings results on Oct 17, 2026. The company reported ₹7 earnings per share for the quarter, beating the consensus estimate of ₹5.9 by ₹1.1.

Is Rossari Biotech Ltd overvalued?

According to Wall Street analysts Rossari Biotech Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Rossari Biotech Ltd pay dividends?

Rossari Biotech Ltd pays a Annually dividend of ₹0.5 which represents an annual dividend yield of 0.11%. See more information on Rossari Biotech Ltd dividends here

What is Rossari Biotech Ltd’s EPS estimate?

Rossari Biotech Ltd’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Rossari Biotech Ltd have?

Rossari Biotech Ltd has 55,394,115 shares outstanding.

What happened to Rossari Biotech Ltd’s price movement after its last earnings report?

Rossari Biotech Ltd reported an EPS of ₹7 in its last earnings report, beating expectations of ₹5.9. Following the earnings report the stock price went down -1.947%.

Which hedge fund is a major shareholder of Rossari Biotech Ltd?

Currently, no hedge funds are holding shares in IN:ROSSARI

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Rossari Biotech Ltd

Rossari Biotech Limited, an India-based company, is a global manufacturer and distributor of specialized chemical products. Its diverse offerings cater to numerous industries, including ingredients for soaps and detergents, formulations for inks, paints, and coatings, materials for ceramics and tiles, solutions for pulp and paper production, components for cement, and water treatment compounds. The company also provides a broad spectrum of textile processing chemicals, supporting various fabrics like cotton, polyester, acrylic, wool, silk, and nylon, alongside functional finishes, denim treatments, and eco-friendly options. Additionally, Rossari Biotech develops pet grooming essentials such as natural shampoos, powders, deodorants, sprays, creams, and floor cleaners, marketed under brands like Lozalo, Hunger Fills, and Sniffy. Its portfolio extends to poultry nutrition products, encompassing vitamin-mineral blends, toxin binders, enzyme preparations, liquid nutraceuticals, and herbal supplements. Founded in 2003, the firm, initially named Rossari Labtech, rebranded to Rossari Biotech Limited in December of the same year and is headquartered in Mumbai, India.